Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution

Tzu Kang Lin, Tu Hsueh Yeh, Peng Wei Hsu, Chih Cheng Chuang, Po Hsun Tu, Pin Yuan Chen, Shih Ming Jung, Kuo Chen Wei, Yin Cheng Huang

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Background Primary central nervous system lymphomas (PCNSLs) are relatively rare brain tumors. Accurate diagnosis is usually made by surgical biopsy. In addition to surgical biopsy and decompression, treatment options include high-dose methotrexate and chemotherapy, radiation therapy, and stem cell therapy. Because of the rarity of this disease, guidelines for PCNSL diagnosis and treatment usually are formed from a large series of experiences. Methods We retrospectively reviewed 79 patients in our tertiary referral center during a 13-year period. All patients with PCNSL underwent surgical or bone marrow biopsy procedures, and diagnoses were confirmed by hematologists or neuropathologists. At the time of diagnosis, 44 patients presented with a single lesion. Human immunodeficiency virus was confirmed positive in 1 patient. The standard therapy protocol included high-dose methotrexate (intravenous and intrathecal) and chemotherapy with cytosine arabinoside, followed by external irradiation of the brain. Results Significant prognostic factors in these patients were low serum lactate dehydrogenase levels and radiation therapy. Multiplicity of lesions at time of diagnosis did not imply a worse outcome, and surgical resection and debulking did not show a significant survival benefit. Conclusions PCNSL has a poor prognosis. Further clinical trials and diagnostic tools are needed to reveal the complexity of this disease.
原文英語
頁(從 - 到)550-556
頁數7
期刊World Neurosurgery
103
DOIs
出版狀態已發佈 - 七月 1 2017

指紋

Lymphoma
Central Nervous System
Brain
Biopsy
Methotrexate
Radiotherapy
Surgical Decompression
Drug Therapy
Cytarabine
Cell- and Tissue-Based Therapy
L-Lactate Dehydrogenase
Tertiary Care Centers
Brain Neoplasms
Stem Cells
Therapeutics
Bone Marrow
Clinical Trials
HIV
Guidelines
Survival

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

引用此文

Primary Central Nervous System Lymphomas of the Brain : A Retrospective Analysis in a Single Institution. / Lin, Tzu Kang; Yeh, Tu Hsueh; Hsu, Peng Wei; Chuang, Chih Cheng; Tu, Po Hsun; Chen, Pin Yuan; Jung, Shih Ming; Wei, Kuo Chen; Huang, Yin Cheng.

於: World Neurosurgery, 卷 103, 01.07.2017, p. 550-556.

研究成果: 雜誌貢獻文章

Lin, Tzu Kang ; Yeh, Tu Hsueh ; Hsu, Peng Wei ; Chuang, Chih Cheng ; Tu, Po Hsun ; Chen, Pin Yuan ; Jung, Shih Ming ; Wei, Kuo Chen ; Huang, Yin Cheng. / Primary Central Nervous System Lymphomas of the Brain : A Retrospective Analysis in a Single Institution. 於: World Neurosurgery. 2017 ; 卷 103. 頁 550-556.
@article{551f8d0333ca4c60b961fc0161e8bc78,
title = "Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution",
abstract = "Background Primary central nervous system lymphomas (PCNSLs) are relatively rare brain tumors. Accurate diagnosis is usually made by surgical biopsy. In addition to surgical biopsy and decompression, treatment options include high-dose methotrexate and chemotherapy, radiation therapy, and stem cell therapy. Because of the rarity of this disease, guidelines for PCNSL diagnosis and treatment usually are formed from a large series of experiences. Methods We retrospectively reviewed 79 patients in our tertiary referral center during a 13-year period. All patients with PCNSL underwent surgical or bone marrow biopsy procedures, and diagnoses were confirmed by hematologists or neuropathologists. At the time of diagnosis, 44 patients presented with a single lesion. Human immunodeficiency virus was confirmed positive in 1 patient. The standard therapy protocol included high-dose methotrexate (intravenous and intrathecal) and chemotherapy with cytosine arabinoside, followed by external irradiation of the brain. Results Significant prognostic factors in these patients were low serum lactate dehydrogenase levels and radiation therapy. Multiplicity of lesions at time of diagnosis did not imply a worse outcome, and surgical resection and debulking did not show a significant survival benefit. Conclusions PCNSL has a poor prognosis. Further clinical trials and diagnostic tools are needed to reveal the complexity of this disease.",
keywords = "Chemotherapy, Overall survival, Primary CNS lymphoma, Radiation therapy",
author = "Lin, {Tzu Kang} and Yeh, {Tu Hsueh} and Hsu, {Peng Wei} and Chuang, {Chih Cheng} and Tu, {Po Hsun} and Chen, {Pin Yuan} and Jung, {Shih Ming} and Wei, {Kuo Chen} and Huang, {Yin Cheng}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.wneu.2017.03.095",
language = "English",
volume = "103",
pages = "550--556",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Primary Central Nervous System Lymphomas of the Brain

T2 - A Retrospective Analysis in a Single Institution

AU - Lin, Tzu Kang

AU - Yeh, Tu Hsueh

AU - Hsu, Peng Wei

AU - Chuang, Chih Cheng

AU - Tu, Po Hsun

AU - Chen, Pin Yuan

AU - Jung, Shih Ming

AU - Wei, Kuo Chen

AU - Huang, Yin Cheng

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background Primary central nervous system lymphomas (PCNSLs) are relatively rare brain tumors. Accurate diagnosis is usually made by surgical biopsy. In addition to surgical biopsy and decompression, treatment options include high-dose methotrexate and chemotherapy, radiation therapy, and stem cell therapy. Because of the rarity of this disease, guidelines for PCNSL diagnosis and treatment usually are formed from a large series of experiences. Methods We retrospectively reviewed 79 patients in our tertiary referral center during a 13-year period. All patients with PCNSL underwent surgical or bone marrow biopsy procedures, and diagnoses were confirmed by hematologists or neuropathologists. At the time of diagnosis, 44 patients presented with a single lesion. Human immunodeficiency virus was confirmed positive in 1 patient. The standard therapy protocol included high-dose methotrexate (intravenous and intrathecal) and chemotherapy with cytosine arabinoside, followed by external irradiation of the brain. Results Significant prognostic factors in these patients were low serum lactate dehydrogenase levels and radiation therapy. Multiplicity of lesions at time of diagnosis did not imply a worse outcome, and surgical resection and debulking did not show a significant survival benefit. Conclusions PCNSL has a poor prognosis. Further clinical trials and diagnostic tools are needed to reveal the complexity of this disease.

AB - Background Primary central nervous system lymphomas (PCNSLs) are relatively rare brain tumors. Accurate diagnosis is usually made by surgical biopsy. In addition to surgical biopsy and decompression, treatment options include high-dose methotrexate and chemotherapy, radiation therapy, and stem cell therapy. Because of the rarity of this disease, guidelines for PCNSL diagnosis and treatment usually are formed from a large series of experiences. Methods We retrospectively reviewed 79 patients in our tertiary referral center during a 13-year period. All patients with PCNSL underwent surgical or bone marrow biopsy procedures, and diagnoses were confirmed by hematologists or neuropathologists. At the time of diagnosis, 44 patients presented with a single lesion. Human immunodeficiency virus was confirmed positive in 1 patient. The standard therapy protocol included high-dose methotrexate (intravenous and intrathecal) and chemotherapy with cytosine arabinoside, followed by external irradiation of the brain. Results Significant prognostic factors in these patients were low serum lactate dehydrogenase levels and radiation therapy. Multiplicity of lesions at time of diagnosis did not imply a worse outcome, and surgical resection and debulking did not show a significant survival benefit. Conclusions PCNSL has a poor prognosis. Further clinical trials and diagnostic tools are needed to reveal the complexity of this disease.

KW - Chemotherapy

KW - Overall survival

KW - Primary CNS lymphoma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85019924971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019924971&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2017.03.095

DO - 10.1016/j.wneu.2017.03.095

M3 - Article

C2 - 28363832

AN - SCOPUS:85019924971

VL - 103

SP - 550

EP - 556

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -